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Previews(Zhang et al., 2011), in medulloblastoma
high nuclear b-catenin is an established
predictor of increased patient survival
(Ellison et al., 2005). How, then, does
a b-catenin/FoxM1 interaction function
in medulloblastoma, if it exists at all? Do
mutations to b-catenin at key regulatory
residues, which are common in medullo-
blastoma, alter the armadillo repeat-
mediated interaction of b-catenin with
FoxM1? It will be interesting to see what
a more thorough examination of the
FoxM1/b-catenin interaction in medullo-
blastoma can elucidate concerning this
discrepancy.
A further point that the current study
(Zhang et al., 2011) highlights is the
potential for a widespread interaction
between Fox proteins and the Wnt/
b-catenin signaling pathway. Previous
studies in C. elegans and mammalian
cells demonstrated a physical interaction
between b-catenin and multiple FOXO
proteins (Essers et al., 2005). Similar to
the results of Zhang et al. (2011), these
interactions were mediated by the arma-
dillo repeats of b-catenin and the portion
of the FOXO protein containing the fork-
head DNA-binding domain (Essers et al.,
2005). Additionally, there is precedence
for Wnt/b-catenin signaling in the regula-416 Cancer Cell 20, October 18, 2011 ª2011tion of Fox proteins. This is the case for
FoxN1, the protein that is mutated in
nude mice, resulting in athymic and hair-
less animals (Balciunaite et al., 2002). In
the thymus and the hair follicle, Wnt/
b-catenin pathway stimulation leads to
activation of FoxN1, which possesses
Wnt Response Elements (WREs) in its
promoter (Balciunaite et al., 2002). In
fact there may also be a reciprocal rela-
tionship between Wnt/b-catenin and
FoxM1 because FoxM1 can directly bind
to the promoter of human b-catenin and
regulate its expression in endothelial
cells. However, the frequency of cross-
regulation between these two pathways,
in both normal and tumor environments,
remains to be seen. Additionally, whether
FoxM1 can regulate b-catenin nuclear
translocation in other cell contexts has
yet to be established. In any case this
study illuminates the potential for Wnt/
b-catenin pathway control by an unusual
source, FoxM1, and the role for these
proteins in glioblastoma progression.
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Oncolytic viruses exploit molecular differences between normal and cancer cells to selectively kill the latter.
Results of a synthetic lethal screen described in this issue of Cancer Cell demonstrate that components of
the unfolded protein response (UPR) limit virus-induced tumor cell killing and identify a strategy to utilize
this knowledge.Productive viral infection mimics onco-
genic transformation in several respects,
and some of the same molecular mecha-
nisms are employed by viruses and
cancer cells to disrupt key homeostatic
mechanisms. These similarities serve asthe foundation for the development of
‘‘oncolytic’’ viruses that are designed
to specifically target and kill cancer
cells (Parato et al., 2005). Although
some targeting strategies involve engi-
neering viruses so that they bind specifi-cally to cancers, an even more attrac-
tive approach involves developing
viruses that can only replicate in cancer
cells that contain specific defects in
homeostatic control. For example one
of the products of the adenovirus E1B
Figure 1. Viral Infection and the UPR
Under normal conditions the three major arms of the UPR (ATF6, IRE1, and
PERK) are maintained in inactive states via interactions between their ER
luminal domains and the ER chaperone, Grp78/BiP. Viral or misfolded proteins
compete for binding to Grp78, allowing for activation of the UPR. Viral double-
stranded RNA can also promote phosphorylation of eIF2a in normal cells by
activating PKR. Knockdown of either ATF6 or IRE1/XBP1 results in upregula-
tion of the caspase-2 adaptor protein, RAIDD, via unknown mechanisms,
thereby ‘‘preconditioning’’ cells for virus-induced apoptosis. RAIDD-mediated
caspase-2 activation appears to be controlled viamechanisms that involve the
heat-shocked-responsive transcription factor, HSF-1, and perhaps heat-
shocked proteins and other chaperones.
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cally disrupts p53 function,
thereby undermining the
host p53-dependent antiviral
response that would other-
wise result in inhibition of
DNA synthesis and/or ap-
optosis (Debbas and White,
1993). Mutant forms of
adenovirus that lack E1B
55K should only replicate in
cells with defective p53 func-
tion, i.e., cancers. Several
groups have developed E1B
mutant adenoviruses for
cancer therapy, and prom-
ising results have been ob-
tained with several of them,
including Onyx Pharmaceuti-
cals’ ONYX-015 (Khuri et al.,
2000). Another promising ap-
proach exploits the presence
of mutant active Ras (Parato
et al., 2005).
Rhabdoviruses are RNA
viruses that are also being de-
veloped as oncolytic agents.
Their tumor selectivity is re-
lated largely to the fact that
tumor cells are often resistant
to the antiviral effects of type Iinterferons (IFNs), which can completely
suppress viral replication in normal cells
(Stojdl et al., 2000). Eliminating viral
mechanisms that suppress autocrine IFN
production enhances oncolytic activity
while further reducing toxicity to normal
host tissues (Stojdl et al., 2003).
In this issue of Cancer Cell, another
novel strategy to promote their oncolytic
effects has been uncovered (Mahoney
et al., 2011). The investigators designed
a synthetic lethal RNAi screen to identify
cytoprotective pathways that limit tumor
cell killing induced by the Maraba rhab-
dovirus in three different human cancer
cell lines. Their ‘‘hits’’ were enriched for
genes that function within two of the
three major pathways that respond to
endoplasmic reticular (ER) stress, com-
monly referred to as the unfolded protein
response (UPR) (Figure 1). More specifi-
cally, the screen implicated the ATF6
and IRE1/XBP1 pathways (but not the
PERK/eIF2a/ATF4 pathway), as well as
downstream genes involved in the trans-
port of protein aggregates out of the
ER to the proteasome, in cytoprotection.
Importantly, the group also identified anovel small molecule inhibitor of IRE1
that also sensitized tumor but not normal
cells to the oncolytic effects of the virus
in vitro and in xenografts. Therefore, if
the inhibitor can be further optimized to
increase its potency, there is a good
chance that these preclinical observa-
tions can be translated in patients with
cancer.
At first glance it might seem surprising
that hits within the PERK/eIF2a arm of
the UPR were not identified, but in fact
this makes sense. Phosphorylation of
eIF2a results in global downregulation of
cap-dependent host translation, so viruses
have evolved many different mechanisms
to prevent eIF2a phosphorylation or its
downstream consequences in normal
cells (Mohr, 2005). Furthermore, we have
observed that many tumor cells fail to
display increased eIF2a phosphorylation
or translational arrest in response to pro-
teotoxic and ER stress (Zhu et al., 2010;
unpublished data), so this arm of the
UPR may be disabled in a large subset
of cancers anyway. In these cancers the
coupling between the proteasome and
autophagy is disrupted (Zhu et al., 2010),Cancer Cell 20, October 18which may also be advanta-
geous for productive viral
infection if autophagy plays
some role in limiting it (Tallo´czy
et al., 2002).
One might also predict
that knockdown of UPR or
ER-associated decay (ERAD)
components would cause a
buildup of protein aggregates
within the ER and that sub-
sequent viral infection dra-
matically exacerbates the
situation by overwhelming an
already stressed ER-Golgi
network with increased pro-
tein synthetic load. Indeed,
UPR inhibition did cause
features of ER stress in in-
fected cells, but they resolved
quickly and did not lead to
an obvious increase in the
accumulation of protein ag-
gregates (Mahoney et al.,
2011), strongly suggesting
that the sensitization caused
by pretreatment with UPR
inhibitors was not caused
by this mechanism. Rather,
UPR inhibition appeared
to ‘‘precondition’’ the cellsto subsequent virus-induced cell death
by upregulating expression of the cas-
pase adaptor protein, RAIDD, and
promoting activation of caspase-2, and
knockdown of caspase-2 almost
completely rescued the synthetic lethal
interaction between UPR inhibition and
viral infection. Recent work from Doug
Green’s group (Bouchier-Hayes et al.,
2009) demonstrated that RAIDD-medi-
ated caspase-2 activation is controlled
by the stress-responsive transcription
factor, HSF-1, suggesting that heat-
shocked proteins and/or other (perhaps
ER-based?) molecular chaperones may
play central roles in controlling stress-
induced caspase-2 activation (Figure 1).
Left unresolved are the molecular mecha-
nisms that link UPR inhibition to RAIDD
upregulation and viral infection to cas-
pase-2 activation. It does seem likely
that some (possibly subtle) perturbation
of protein aggregate clearance plays a
role, but how, and especially why, this
low-level stress, that appears to be com-
pletely resolved prior to viral infection,
sets the stage for subsequent apoptosis
awaits further investigation., 2011 ª2011 Elsevier Inc. 417
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Fumarate hydratase (FH) is a tumor suppressor, but how it acts is unclear. Two reports in this issue of
Cancer Cell reveal that FH deficiency leads to succination of Keap1, stabilization of Nrf2, and induction of
stress-response genes including HMOX1, which is important for the survival of FH-deficient cells.The fumarate hydratase gene (FH) en-
codes a TCA cycle enzyme and functions
as a tumor suppressor gene. Heterozy-
gous germline FH mutations result in
hereditary leiomyomatosis and renal cell
cancer (HLRCC), a syndrome character-
ized by smooth muscle tumors and papil-
lary renal cell carcinoma type 2 (pRCC-2)
(Tomlinson et al., 2002). In tumors, the
wild-type FH allele is lost, and FH function
is abrogated. pRCC-2 tumors in patients
with HLRCC tend to metastasize early,
and currently, there is no therapy.
How FH suppresses tumor formation is
unknown. FH loss causes fumarate accu-
mulation in tumor cells, and fumarate is
a competitive inhibitor of 2-oxoglutarate-
dependent prolyl hydroxylase domain-
containing proteins (PHD) that hydrox-
ylate HIFa. When hydroxylated, HIFa is
recognized by the pVHL E3 ubiquitin
ligase complex and is degraded. BecauseVHL is frequently mutated in renal cancer
leading to HIF stabilization, a model
whereby HIF is upregulated in pRCC-2
as a consequence of PHD inhibition by
fumarate is attractive. However, the im-
portance of PHD inhibition and HIF stabi-
lization in the development of FH-defi-
cient tumors remains unknown.
Keap1 is the substrate recognition sub-
unit of a Cul3-based E3 ubiquitin ligase
complex that regulates Nrf2, a pivotal
transcription factor in the antioxidant re-
sponse. Keap1 proteins dimerize through
anN-terminal BTB domain, which through
an intervening region (IVR) is linked to a
C-terminal DC domain that contains
a b-propeller made up largely of kelch
repeats (Figure 1A). Two b-propellers in a
Keap1 dimer interact with an Nrf2 mono-
mer. Nrf2 contains two different Keap1-
interacting motifs. Binding through both
motifs is required for Nrf2 degradation,which led to a ‘‘hinge and latch’’ model
(Hayes et al., 2010; Taguchi et al., 2011).
Under normal conditions, Keap1 pro-
motes Nrf2 ubiquitylation and proteoso-
mal-mediated degradation. However, in
the presence of electrophiles or reactive
oxygen species, Keap1 is modified at
several reactive Cys residues, resulting in
Nrf2 stabilization and the activation of a
protective gene expression program that
includes HMOX1, an archetypal stress
response gene (Hayes et al., 2010).
In this issue of Cancer Cell, Ooi et al.
(2011) and Adam et al. (2011) show that
FH loss results in Keap1 inactivation and
Nrf2-dependent activation of antioxidant
pathways. Through gene expression anal-
yses, both groups discovered that FH
deficiency was associated with increased
expression of antioxidant genes, and this
was accompanied by the accumulation
of Nrf2. Reconstitution of FH-deficient
